Gadavist — Competitive Intelligence Brief

Gadavist (GADOBUTROL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gadolinium-based Contrast Agent [EPC]. Area: Hematology.

marketed Gadolinium-based Contrast Agent [EPC] Hematology Small molecule

Target snapshot

Gadavist (GADOBUTROL) — Bayer. Gadavist works by binding to gadolinium ions, which then accumulate in body tissues and enhance MRI signal.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gadavist TARGET	GADOBUTROL	Bayer	marketed	Gadolinium-based Contrast Agent [EPC]		2011-01-01
gadoxetic acid enhanced liver MRI	gadoxetic acid enhanced liver MRI	Seoul National University Hospital	marketed	Gadolinium-based contrast agent	Organic anion transporter 1B1/1B3 (OATP1B1/1B3)
Gadoterate (Dotarem/Clariscan)	Gadoterate (Dotarem/Clariscan)	Bayer	marketed	Gadolinium-based contrast agent	Water protons (via paramagnetic gadolinium ion)
Gadobutrol (Gadovist/Gadavist)	Gadobutrol (Gadovist/Gadavist)	Insel Gruppe AG, University Hospital Bern	marketed	Gadolinium-based contrast agent (GBCA)	Water proton relaxation (T1 relaxation enhancement)
Gadovist®/Gadavist®	Gadovist®/Gadavist®	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)
Gadopentetate-Dimeglumine 0.0125 mmol	Gadopentetate-Dimeglumine 0.0125 mmol	Paracelsus Medical University	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)
DOTAREM	DOTAREM	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 and T2 relaxation times)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gadolinium-based Contrast Agent [EPC] class)

1. Bayer · 1 drug in this class